Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT 1 Patients on Leqvio plus LLT were 43% less likely to ...

Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...

Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently there ...

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic ...

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma ...

Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy ...

Novartis has transformed its Global Health & Corporate Responsibility (GH&CR) organization. The change consolidates and streamlines expertise and resources to achieve a stronger focus on the areas ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...

Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9 million ...

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU ...